Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of depletion of LRIG1 on polyclonal CD8+ tumor infiltrating T cells and Effect of depletion of LRIG1 on OT1 CD8+ tumor-infiltrating T cells

ABSTRACT: To investigate the function of LRIG11 in regulating the differentiation of polyclonal CD8 tumor infiltrating T cells during the response to B16melanoma. And, To investigate the function of LRIG1 in regulating the activaiton of ovalbumin specific OT1 CD8+ T cells during the response to B16 tumor stably expresss ovalbumin as surrogate tumor antigen.

ORGANISM(S): Mus musculus

PROVIDER: GSE245841 | GEO | 2024/01/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Effect of depletion of LRIG1 on CD8+ tumor infiltrating T cells [CITE-Seq]

Project description:To investigate the function of LRIG11 in regulating the differentiation of polyclonal CD8 tumor infiltrating T cells during the response to B16melanoma, we isolated CD8 T cells on day 18 post vaccine treatment and examined gene transcription at single cell level

2024-01-02 | GSE245840 | GEO

lncRNA NDRG1-OT1 downstream gene microarray

Project description:To investigate the target gene of lncRNA NDRG1-OT1 in breast cancer

2017-12-31 | GSE72881 | GEO

WT and CXCR6KO OT1 T cells

Project description:WT and KO OT1 T cells were isolated from vaccinia-OVA infected ears 21 days post infection

2023-08-08 | GSE223727 | GEO

Impact of SOCS1 inactivation on OT1 adoptive cell transfer in B16-OVA melanoma C57BL/6 bearing mice

Project description:Role of SOCS1 inactivation on OT1 transferred T cells anti-tumor activity in B16-OVA melanoma tumoirs

2021-09-02 | GSE154792 | GEO

RNA sequencing analysis of anti-CD3/CD28 stimulated wild type-OT1 (WT) and Lrch1-/- -OT1 (KO) CD8+ T cells

Project description:RNA sequencing analysis of anti-CD3/CD28 stimulated wild type-OT1 (WT) and Lrch1-/- -OT1 (KO) CD8+ T cells

| PRJNA633049 | ENA

Effect of depletion of LRIG1 on CD8+ tumor infiltrating T cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-01-02 | GSE245842 | GEO

OT1 T cell activation time course

Project description:Time course of OT1 T cell activation with SIINFEKL peptide.

2020-02-25 | PXD016443 | Pride

RNA sequencing analysis of anti-CD3/CD28 stimulated wild type-OT1 (WT) and Lrch1-/- -OT1 (KO) CD8+ T cells

Project description:We report the differential gene expression between anti-CD3/CD28 stimulated WT and LRCH1-deficient CD8+ T cells. Improving cytotoxicity, proliferation and infiltration ability of CD8+ T cells is critical in T cell immunotherapies against tumors. This study has identified LRCH1 as a negative regulator of LAT-mediated TCR signal transduction, as LRCH1 inhibits LAT signalosome formation and facilitates the endocytosis of LAT on the plasma membrane. LRCH1-deficient CD8+ T cells are more proliferative and effective at pathogen control and tumor elimination. Importantly, CRISPR/Cas9-mediated knockout of LRCH1 in human T cells also increases IFN-γ production, cell proliferation and migration ability in vitro. These data suggest LRCH1 as a potential target to improve CD8+ T cell responses against tumor and pathogens.

2020-07-29 | GSE150634 | GEO

Haematobacter massiliensis strain:OT1

Project description:Haematobacter massiliensis OT1 Genome sequencing and assembly

| PRJNA517385 | ENA

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

Project description:The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies. The TIL selection process is based on evidence showing that CD8+ TIL which co-express both CD39 and CD103 harbor the bulk of tumor-reactivity and that the remaining CD8 TIL is mainly composed of non-tumor reactive bystander cells. All of the expanded TIL that are produced (1-40 billion are expected) will be delivered in the form of a cell suspension to the participants by intravenous infusion. It is proposed that these selected TIL will produce a more potent and efficacious treatment of late-stage cancer.

| 63320 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data